New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 11, 2012
11:25 EDTDKAM, DKAM, LTBR, LTBR, NBS, NBS, LQMT, LQMT, NVTL, NVTL, ASUR, ASUR, GALE, GALE, LLTC, LLTC, AEMD, AEMD, TAS, TAS, COPY, COPY, CDXC, CDXC, LLEN, LLEN, LPH, LPHRedChip Companies to host a conference
15th Annual Small-Cap Conference is being held in San Francisco on October 15 with webcasted company presentations to begin at 11:30 am. Webcast Link
News For LPH;LLEN;CDXC;COPY;TAS;AEMD;LLTC;GALE;ASUR;NVTL;LQMT;NBS;LTBR;DKAM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
07:35 EDTNBSNeoStem says NBS20 receives ATMP classification from EMA
Subscribe for More Information
April 23, 2015
07:07 EDTASUR, LTBRRedChip to hold a virtual conference
Subscribe for More Information
April 22, 2015
07:16 EDTLTBR, ASURRedChip to hold a virtual conference
Subscribe for More Information
April 21, 2015
09:34 EDTGALEGalena sent FDA warning letter following site inspection
A warning letter published by the FDA, dated April 3, states that the agency's inspection of Galena Biopharma's site in Portland, Oregon, conducted between November 17 and 21, 2014, revealed "serious violations" of FDAs PADE reporting requirements. Reference Link
April 20, 2015
07:32 EDTNBSNeoStem announces expanded cell therapy relationship with Kite Pharma
Subscribe for More Information
April 16, 2015
10:15 EDTLLTCOptions with decreasing implied volatility
Subscribe for More Information
April 15, 2015
11:57 EDTLLTCLinear Technology says has positive book-to-bill going into Q4
11:42 EDTLLTCLinear Technology says industrial was largest percentage of bookings in quarter
Subscribe for More Information
11:19 EDTASURAsure Software management to meet with Barrington
Meeting to be held in Canada on April 16 hosted by Barrington.
10:19 EDTLLTCOptions with decreasing implied volatility
Subscribe for More Information
09:55 EDTLLTCBofA/Merrill U.S. autos analysts hold an analyst/industry conference call
Subscribe for More Information
08:12 EDTAEMDAethlon Medical announces cancer clinical trial agreement
Subscribe for More Information
April 14, 2015
17:03 EDTLLTCLinear Technology sees Q4 revenue growth 2%-5%
"Looking forward we expect growth to continue in the June quarter although moderately tempered by worldwide macroeconomic conditions. Accordingly, we are currently estimating sequential revenue growth of 2%-5% for Q4, said the company. Revenue consensus is $388.06M
17:01 EDTLLTCLinear Technology reports Q3 EPS 55c, consensus 53c
Subscribe for More Information
15:34 EDTLLTCNotable companies reporting after market close
Subscribe for More Information
11:35 EDTCDXCChromaDex management to meet with Roth Capital
Meeting to be held in Chicago on April 20 hosted by Roth Capital.
08:08 EDTAEMDAethlon Medical announces effectiveness of reverse stock split
Subscribe for More Information
07:26 EDTGALEGalena completes over-enrollment of NeuVax Phase 3 PRESENT clinical trial
Galena Biopharma announced the completion of enrollment in the NeuVax Phase 3 PRESENT, or Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment, clinical trial. NeuVax is a first-in-class, HER2-directed cancer immunotherapy under evaluation to prevent breast cancer recurrence after standard of care treatment in the adjuvant setting. As anticipated, Galena over-enrolled the trial by 7.7% with a total of 758 patients now in the intent-to-treat, or ITT, population. The protocol for the PRESENT trial, being conducted under an FDA approved Special Protocol Assessment, or SPA, called for 700 patients; and, the company expects this higher number of ITT patients will increase the confidence in both the timing and quality of the statistics and the final outcome of the trial. The primary endpoint is currently expected to be reached in 2018, after the last patient dosed reaches her 36th month of treatment, or a total of 141 events occur, whichever comes later.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use